Form 4: Bionano Genomics Director Yvonne Linney Granted Stock Options

Bionano Genomics, Inc. Director Yvonne Linney was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Summary

• Yvonne Linney, a Director at Bionano Genomics, Inc. (BNGO), was granted 2,775 stock options.
• The transaction date for the option grant was June 11, 2025.
• The exercise price for these stock options is $3.67 per share.
• The options will vest in equal monthly installments over 12 months from the grant date.
• Full vesting will occur by the date of the Company's next annual stockholder meeting, subject to continuous service.
• The options will also fully vest upon a Change of Control, as defined in the Company's 2018 equity incentive plan.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Ms. Linney beneficially owns 2,775 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It is a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive horizon.

Future Outlook

The stock options are subject to a vesting schedule over the next 12 months, or until the next annual stockholder meeting, indicating a future alignment of the director's compensation with company performance and continued service. Full vesting is also tied to a potential Change of Control event.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across industries to incentivize and retain key personnel, aligning their financial interests with the long-term success of the company.

Corporate Governance

Related Party Transactions

• The grant of stock options to Yvonne Linney, a Director of Bionano Genomics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value, potentially leading to improved governance and performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for equity-based incentives within the company.

Next Steps

• The stock options will vest in equal monthly installments over the 12 months following the grant date, or fully by the next annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Bionano Genomics, BNGO, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Incentive Plan